Abstract
The introduction of stem cells in cardiology provides new tools in understanding the regenerative processes of the normal and pathologic heart and opens new options for the treatment of cardiovascular diseases. The feasibility of adult bone marrow autologous and allogenic cell therapy of ischemic cardiomyopathies has been demonstrated in humans. However, many unresolved questions remain to link experimental with clinical observations. The demonstration that the heart is a self-renewing organ and that its cell turnover is regulated by myocardial progenitor cells offers novel pathogenetic mechanisms underlying cardiac diseases and raises the possibility to regenerate the damaged heart. Indeed, cardiac stem progenitor cells (CSPCs) have recently been isolated from the human heart by several laboratories although differences in methodology and phenotypic profile have been described. The present review points to the potential role of CSPCs in the onset and development of congestive heart failure and its reversal by regenerative approaches aimed at the preservation and expansion of the resident pool of progenitors.
Keywords: Stem cells, myocardial regeneration, cardiovascular diseases, cardiac stem progenitor cells (CSPCs), cardiogenesis, cell migration, cardiomyocytes, smooth muscle cells, endothelial cells, gene expression
Current Pharmaceutical Design
Title: Resident Cardiac Stem Cells
Volume: 17 Issue: 30
Author(s): Stilli D., Quaini F., Quaini E., Anversa P., Kajstura J., Leri A., Urbanek K., Rossi F., De Angelis A., Falco A., Rossini A., Frati C., Musso E., Madeddu D., Ferraro F., Mangiaracina C., Rossetti P., Prezioso L., Cavalli S., Lagrasta C., Graiani G. and Savi M.
Affiliation:
Keywords: Stem cells, myocardial regeneration, cardiovascular diseases, cardiac stem progenitor cells (CSPCs), cardiogenesis, cell migration, cardiomyocytes, smooth muscle cells, endothelial cells, gene expression
Abstract: The introduction of stem cells in cardiology provides new tools in understanding the regenerative processes of the normal and pathologic heart and opens new options for the treatment of cardiovascular diseases. The feasibility of adult bone marrow autologous and allogenic cell therapy of ischemic cardiomyopathies has been demonstrated in humans. However, many unresolved questions remain to link experimental with clinical observations. The demonstration that the heart is a self-renewing organ and that its cell turnover is regulated by myocardial progenitor cells offers novel pathogenetic mechanisms underlying cardiac diseases and raises the possibility to regenerate the damaged heart. Indeed, cardiac stem progenitor cells (CSPCs) have recently been isolated from the human heart by several laboratories although differences in methodology and phenotypic profile have been described. The present review points to the potential role of CSPCs in the onset and development of congestive heart failure and its reversal by regenerative approaches aimed at the preservation and expansion of the resident pool of progenitors.
Export Options
About this article
Cite this article as:
D. Stilli, F. Quaini, E. Quaini, P. Anversa, J. Kajstura, A. Leri, K. Urbanek, F. Rossi, Angelis A. De, A. Falco, A. Rossini, C. Frati, E. Musso, D. Madeddu, F. Ferraro, C. Mangiaracina, P. Rossetti, L. Prezioso, S. Cavalli, C. Lagrasta, G. Graiani and M. Savi, Resident Cardiac Stem Cells, Current Pharmaceutical Design 2011; 17 (30) . https://dx.doi.org/10.2174/138161211797904181
DOI https://dx.doi.org/10.2174/138161211797904181 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications
Current Pharmaceutical Design Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) Updated Electrocardiographic Classification of Acute Coronary Syndromes
Current Cardiology Reviews Current Algorithms for the Diagnosis of wide QRS Complex Tachycardias
Current Cardiology Reviews Mesenchymal Stem Cell Therapy for Acetaminophen-related Liver Injury: A Systematic Review and Meta-analysis of Experimental Studies <i>In Vivo</i>
Current Stem Cell Research & Therapy Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinsons Disease
Mini-Reviews in Medicinal Chemistry Hypertension and Angiogenesis
Current Pharmaceutical Design L-Arginine Availability as a Pathological Mechanism in Essential Hypertension, Chronic Renal and Heart Failure
Vascular Disease Prevention (Discontinued) Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design ULK1 Plays a Critical Role in AMPK-Mediated Myocardial Autophagy and Contractile Dysfunction following Acute Alcohol Challenge
Current Pharmaceutical Design Editorial [Hot Topic: Vascular Complications of Diabetes (Executive Editor: Olga I. Stenina)]
Current Pharmaceutical Design Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry The Role of microRNAs in Cardiovascular Disease
Current Medicinal Chemistry Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets